Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 273 of 5804
-
Could ozempic help men become fathers? new trial investigates
Disease control Not yet recruitingWhy is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semag…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 26, 2026 17:30 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThe main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Double radiation attack aims to stop prostate cancer bone breaks
Disease control Not yet recruitingProstate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer. Administered intravenously, it enables targeted irradiation of PSMA-expressing tumor cells. However, 30-50% of patient…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug targets brain tumors in lung cancer patients
Disease control Not yet recruitingA single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Phase: PHASE2 • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New gene therapy hopes to fix fatal brain diseases
Disease control Not yet recruitingThe project aims to optimize and validate this new therapeutic strategy using cells from GM2 patients to evaluate the cross-correction of neurons in vitro by the culture medium of genetically modified myeloid cell lines. The ultimate goal is to demonstrate the potential of CHS-TG…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New shot could tame inherited high cholesterol
Disease control Not yet recruitingThis Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Triple attack on prostate cancer: drug, surgery, and radiation aim to stop spread
Disease control Not yet recruitingProstate cancer represents the second most common malignancy in men worldwide. Oligometastatic prostate cancer (OMPC), defined as a transitional state between localized and widespread metastatic disease (≤10 metastatic lesions without visceral metastases), exhibits relatively ind…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for advanced penile cancer: drug combo targets tough cases
Disease control Not yet recruitingPenile cancer is a rare malignant tumor of the male genitourinary system, with 95% being squamous cell carcinoma. Due to social factors, delayed diagnosis is common, leading to a high rate of lymph node metastasis (17%-45% at diagnosis), which significantly impairs quality of lif…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for rare kidney cancer: targeted drug plus radiation may replace chemo
Disease control Not yet recruitingThis randomized, open-label, multicenter phase II study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU). Eli…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on recurrent brain tumors
Disease control Not yet recruitingThis clinical study is designed to evaluate the safety and efficacy of IL13Rα2 CAR-T cells secreting anti-PD-L1 antibody in patients with recurrent malignant glioma. This trial is a multicenter, open-label, non-randomized, single-arm investigator-initiated trial (IIT). Patients w…
Phase: PHASE1 • Sponsor: Ming Yang • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Shorter radiation with Real-Time adjustments could reduce side effects
Disease control Not yet recruitingThis phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2) external beam radiotherapy compared with standard-of-care…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug cocktail takes aim at rare, aggressive cancers
Disease control Not yet recruitingTo explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy aims to boost depression treatment success
Symptom relief Recruiting nowRepetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New CAR-T therapy takes aim at tough lymphoma cancers
Disease control Not yet recruitingThis study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New blood test could spot pancreatic cancer earlier
Diagnosis Not yet recruitingThe purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this st…
Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to cut opioid use after heart and Weight-Loss surgery
Symptom relief Recruiting nowThis is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowGraft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly affecting survival and quality of life. Acute GVHD (aGVHD) typically occurs within 100 days post-transplant, commonly involving skin, gastr…
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to stop anemia after stem cell transplants
Disease control Not yet recruitingAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there…
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo aims to turn untreatable lung tumors into surgical candidates
Disease control Not yet recruitingThe goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NS…
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo before surgery shows promise
Disease control Not yet recruitingThis is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1 monoclonal antibody) in patients with resectable rec…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC